CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Voloridge Investment Management LLC

Voloridge Investment Management LLC trimmed its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 68.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 52,835 shares of the company's stock after selling 113,428 shares during the period. Voloridge Investment Management LLC owned approximately 0.06% of CRISPR Therapeutics worth $2,080,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Magnetar Financial LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth $359,000. Baker BROS. Advisors LP lifted its position in CRISPR Therapeutics by 55.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock valued at $51,483,000 after buying an additional 464,936 shares during the last quarter. Vanguard Group Inc. boosted its stake in CRISPR Therapeutics by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock worth $68,329,000 after buying an additional 10,579 shares during the period. KBC Group NV increased its position in shares of CRISPR Therapeutics by 2,047.4% during the fourth quarter. KBC Group NV now owns 60,514 shares of the company's stock valued at $2,382,000 after acquiring an additional 57,696 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at about $3,231,000. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Price Performance

Shares of CRSP stock traded up $0.66 during trading hours on Monday, reaching $36.95. 2,374,171 shares of the stock were exchanged, compared to its average volume of 1,712,153. The business's fifty day moving average is $36.54 and its two-hundred day moving average is $41.32. The firm has a market capitalization of $3.19 billion, a P/E ratio of -8.46 and a beta of 1.88. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter last year, the firm posted ($1.43) EPS. The company's revenue was up 71.6% compared to the same quarter last year. As a group, equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the sale, the chief operating officer now owns 8,263 shares of the company's stock, valued at approximately $350,516.46. This trade represents a 12.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Naimish Patel sold 3,932 shares of the company's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the transaction, the insider now directly owns 6,068 shares of the company's stock, valued at $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,953 shares of company stock worth $736,087. Corporate insiders own 4.30% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on CRSP shares. JMP Securities restated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, May 21st. Barclays decreased their price target on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research note on Friday, May 9th. Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price objective for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Morgan Stanley boosted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a report on Friday, February 14th. Finally, Stifel Nicolaus lowered their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.